Athenex exits 503b sterile compounding business

Full-year 2022 product sales guidance maintained at 20-25% growth year-over-year full-year 2022 product sales guidance maintained at 20-25% growth year-over-year
ATNX Ratings Summary
ATNX Quant Ranking